JP2004501955A - リポソーム抗新生物薬剤およびその使用 - Google Patents

リポソーム抗新生物薬剤およびその使用 Download PDF

Info

Publication number
JP2004501955A
JP2004501955A JP2002506699A JP2002506699A JP2004501955A JP 2004501955 A JP2004501955 A JP 2004501955A JP 2002506699 A JP2002506699 A JP 2002506699A JP 2002506699 A JP2002506699 A JP 2002506699A JP 2004501955 A JP2004501955 A JP 2004501955A
Authority
JP
Japan
Prior art keywords
drug
liposome
active agent
liposomes
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002506699A
Other languages
English (en)
Japanese (ja)
Inventor
マデン，　トーマス　ディー．
センプル，　シーン　シー．
アーコン，　クエト　エフ．
Original Assignee
アイネックス　ファーマシューティカルズ　コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイネックス　ファーマシューティカルズ　コーポレイション filed Critical アイネックス　ファーマシューティカルズ　コーポレイション
Publication of JP2004501955A publication Critical patent/JP2004501955A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002506699A 2000-06-30 2001-06-29 リポソーム抗新生物薬剤およびその使用 Withdrawn JP2004501955A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21555600P 2000-06-30 2000-06-30
US26461601P 2001-01-26 2001-01-26
PCT/CA2001/000925 WO2002002077A2 (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012025785A Division JP2012092148A (ja) 2000-06-30 2012-02-09 リポソーム抗新生物薬剤およびその使用

Publications (1)

Publication Number Publication Date
JP2004501955A true JP2004501955A (ja) 2004-01-22

Family

ID=26910152

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002506699A Withdrawn JP2004501955A (ja) 2000-06-30 2001-06-29 リポソーム抗新生物薬剤およびその使用
JP2012025785A Pending JP2012092148A (ja) 2000-06-30 2012-02-09 リポソーム抗新生物薬剤およびその使用
JP2014027576A Pending JP2014088444A (ja) 2000-06-30 2014-02-17 リポソーム抗新生物薬剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012025785A Pending JP2012092148A (ja) 2000-06-30 2012-02-09 リポソーム抗新生物薬剤およびその使用
JP2014027576A Pending JP2014088444A (ja) 2000-06-30 2014-02-17 リポソーム抗新生物薬剤およびその使用

Country Status (12)

Country Link
US (7) US7244448B2 (https=)
EP (2) EP1299085B1 (https=)
JP (3) JP2004501955A (https=)
CN (1) CN1245977C (https=)
AT (2) ATE309787T1 (https=)
AU (3) AU2001270413A1 (https=)
CA (2) CA2412795C (https=)
DE (2) DE60115044T2 (https=)
ES (1) ES2253398T3 (https=)
IL (2) IL153676A0 (https=)
MX (1) MXPA02012817A (https=)
WO (2) WO2002002078A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
JP2008519045A (ja) * 2004-11-05 2008-06-05 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
JP2009520774A (ja) 2005-12-22 2009-05-28 アバンテイス・フアルマ・エス・アー コンブレタスタチンおよび抗癌剤を含む組合せ
JP2012092148A (ja) * 2000-06-30 2012-05-17 Tekmira Pharmaceuticals Corp リポソーム抗新生物薬剤およびその使用
US9801874B2 (en) 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
US11559486B2 (en) 2015-07-22 2023-01-24 Acrotech Biopharma, LLC Ready-to-use formulation for Vincristine Sulfate Liposome Injection

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7452550B2 (en) * 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
EP1355634B8 (en) 2000-11-09 2009-03-04 Neopharm, Inc. Sn-38 lipid complexes and methods of use
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
EP1545459A4 (en) * 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP2007522085A (ja) * 2003-06-27 2007-08-09 スミスクライン・ビーチャム・コーポレイション 安定化されたトポテカンリポソーム組成物および方法
DE602004021713D1 (de) * 2003-11-14 2009-08-06 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
WO2005072776A2 (en) * 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
CA2559722A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
EP1750673B1 (en) * 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
KR100889139B1 (ko) * 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
WO2006014035A1 (en) * 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006037230A1 (en) * 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
CN100348194C (zh) * 2005-07-26 2007-11-14 康辰医药发展有限公司 盐酸洛拉曲克的脂质体制剂及其制备方法
CN100375621C (zh) * 2005-11-04 2008-03-19 唐星 长春瑞滨脂质微球注射液及其制备方法
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
US20100093873A1 (en) * 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
US9542001B2 (en) 2010-01-14 2017-01-10 Brainlab Ag Controlling a surgical navigation system
EP2632264B1 (en) * 2010-10-29 2019-10-02 Health Research, Inc. Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US10238602B2 (en) * 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10449193B2 (en) * 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US8753674B2 (en) * 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
WO2014191569A1 (en) * 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AU2015269699B2 (en) 2014-06-03 2020-08-13 Avanti Polar Lipids, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
EP3229776B1 (en) * 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US11318131B2 (en) * 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
AU2017257496B2 (en) 2016-04-27 2020-05-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
RU2734900C1 (ru) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12350271B2 (en) * 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
TWI737974B (zh) * 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
BR112021018739A2 (pt) 2019-03-29 2022-05-03 Dicerna Pharmaceuticals Inc Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
AU2020268798A1 (en) 2019-05-03 2021-11-04 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
JP2023508881A (ja) * 2019-12-20 2023-03-06 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
MX2022008738A (es) 2020-01-15 2022-09-23 Dicerna Pharmaceuticals Inc Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos.
KR20230061389A (ko) 2020-08-04 2023-05-08 다이서나 파마수이티컬, 인크. 올리고뉴클레오티드의 전신 전달
JPWO2022250013A1 (https=) 2021-05-24 2022-12-01
TW202313032A (zh) 2021-05-24 2023-04-01 日商富士軟片股份有限公司 處置劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504517A (ja) * 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
AU7128887A (en) * 1986-02-10 1987-08-25 Liposome Technology, Inc. Controlled-release liposome delivery system
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
CZ104197A3 (en) * 1994-10-05 1997-09-17 Glaxo Wellcome Inc Pharmaceutical preparation
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2269758C (en) 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
KR100679906B1 (ko) 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
JP2004501955A (ja) * 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
CA2424345A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504517A (ja) * 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012092148A (ja) * 2000-06-30 2012-05-17 Tekmira Pharmaceuticals Corp リポソーム抗新生物薬剤およびその使用
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
JP2008519045A (ja) * 2004-11-05 2008-06-05 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
JP2009520774A (ja) 2005-12-22 2009-05-28 アバンテイス・フアルマ・エス・アー コンブレタスタチンおよび抗癌剤を含む組合せ
US9801874B2 (en) 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
US11559486B2 (en) 2015-07-22 2023-01-24 Acrotech Biopharma, LLC Ready-to-use formulation for Vincristine Sulfate Liposome Injection

Also Published As

Publication number Publication date
US20040170678A1 (en) 2004-09-02
WO2002002078A2 (en) 2002-01-10
US20020110586A1 (en) 2002-08-15
ES2253398T3 (es) 2006-06-01
DE60115045T2 (de) 2006-08-03
JP2014088444A (ja) 2014-05-15
WO2002002077A2 (en) 2002-01-10
US7244448B2 (en) 2007-07-17
US20060269594A1 (en) 2006-11-30
JP2012092148A (ja) 2012-05-17
US20110086826A1 (en) 2011-04-14
IL153676A0 (en) 2003-07-06
EP1299084B1 (en) 2005-11-16
CA2412790C (en) 2012-11-06
MXPA02012817A (es) 2004-07-30
DE60115045D1 (de) 2005-12-22
WO2002002077A3 (en) 2002-12-12
US20130136787A1 (en) 2013-05-30
AU2001270413A1 (en) 2002-01-14
CA2412795A1 (en) 2002-01-10
DE60115044T2 (de) 2006-08-03
US20020119990A1 (en) 2002-08-29
CN1245977C (zh) 2006-03-22
US20060093662A1 (en) 2006-05-04
ATE309787T1 (de) 2005-12-15
EP1299085A2 (en) 2003-04-09
EP1299085B1 (en) 2005-11-16
CN1446079A (zh) 2003-10-01
AU2001270385B2 (en) 2006-05-25
EP1299084A2 (en) 2003-04-09
US7060828B2 (en) 2006-06-13
DE60115044D1 (de) 2005-12-22
IL153676A (en) 2007-06-17
AU7038501A (en) 2002-01-14
CA2412790A1 (en) 2002-01-10
CA2412795C (en) 2012-10-02
ATE309786T1 (de) 2005-12-15
WO2002002078A3 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
EP1299084B1 (en) Liposomal antineoplastic drugs and uses thereof
AU2001270385A1 (en) Liposomal antineoplastic drugs and uses thereof
JP5645954B2 (ja) イリノテカン又はその塩酸塩のリポソーム及びその製造方法
ES2198970T3 (es) Inhibidores de topoisomerasa atrapados en liposomas.
JPH11513392A (ja) ミトザントロンのリポソーム製剤
Fatima et al. Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs
CN103622912B (zh) 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
JP2006514016A (ja) リポソーム処方物
US7452550B2 (en) Liposomal antineoplastic drugs and uses thereof
EP1448165B1 (en) Lipid carrier compositions and methods for improved drug retention
Gajera et al. An overview of FDA approved liposome formulations for cancer therapy
US20060193902A1 (en) Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
Hao et al. In vitro and in vivo studies of different liposomes containing topotecan
CN103520159A (zh) 奎宁类药物和长春新碱类药物共载脂质体及其制备方法
YI Liposomal co-encapsulation of quercetin with synergistic chemotherapeutic drugs for breast cancer treatment
Abraham The use of manganese ion gradients in the preparation of anticancer drug formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111115

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120123

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120302